Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses

• Published in: Tissue antigens 2006-05, Vol.67 (5), p.368-376
• Main Authors: Du, Y.-C., Lin, P., Zhang, J., Lu, Y.-R., Ning, Q.-Z., Wang, Q.
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - pharmacology; Animals; Cancer Vaccines - immunology; Cancer Vaccines - therapeutic use; Carcinoma, Lewis Lung - immunology; Cell Fusion; Cell Line, Tumor; CpG-ODN; DC vaccine; Dendritic Cells - drug effects; Dendritic Cells - immunology; DNA - pharmacology; Female; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Neoplasms - drug therapy; Neoplasms - prevention & control; Oligodeoxyribonucleotides; Rats; T-Lymphocytes - immunology; tumor immunotherapy
• ISSN: 0001-2815; 1399-0039
• DOI: 10.1111/j.1399-0039.2006.00590.x

Immunogenicity of tumor cells is generally weak. Therefore, dendritic cells (DCs) have been used to boost anti‐tumor responses of DC‐based vaccines. DC function is highly dependent on its subsets and the level of its maturation. Nowadays, DC/tumor cell fusion vaccines are already used in clinical trials, and there are numerous studies discussing the effects of cytidine‐phosphate‐guanosine‐containing oligonucleotides (CpG‐ODN) on various cell types including DC. CpG‐ODN a powerful immuno‐stimulant can drive DCs fully mature, thus improve the efficacy of vaccine therapy. There are two simple ways to help load tumor antigens onto DCs by direct contact with cells themselves: fusion or co‐culture of DCs with whole tumor cells. In this study, we combined these two approaches to improve the efficacy of DC/tumor cell‐based vaccine. Mature DCs are adept at presenting processed Ag to T cells with loss of its capacity to capture Ag, while immature DCs are on the contrary. Our results emphasize the necessity of considering the stage of DC maturation and corresponding choice of tumor antigen delivery when designing approaches for prophylaxis or therapy of tumors using DC‐based immunization protocols. We used CpG‐ODN‐1826‐stimulated mature DCs and non‐CpG‐ODN‐stimulating DCs as sources of tumor antigen carriers to investigate the appropriate Ag‐loading ways between fusion and co‐culture. Our results displayed that DC/tumor vaccine using CpG‐ODN‐stimulating mature DCs fused, not co‐cultured, with tumor cells can generate a consistent and highly effective anti‐tumor immune responses in vivo.